AA
REGN icon

Addison Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Addison Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.27K Sell
12
-1
-8% -$766 ﹤0.01% 665
2025
Q4 		$10K Buy
13
+2
+18% +$1.36K ﹤0.01% 628
2025
Q3 		$6.19K Buy
11
+4
+57% +$2.26K ﹤0.01% 683
2025
Q2 		$3.67K Sell
7
-9
-56% -$5.02K ﹤0.01% 726
2025
Q1 		$10.1K Sell
16
-8
-33% -$5.5K ﹤0.01% 580
2024
Q4 		$17.1K Buy
24
+10
+71% +$8.39K ﹤0.01% 521
2024
Q3 		$14.7K Sell
14
-2
-13% -$2.23K ﹤0.01% 547
2024
Q2 		$16.8K Sell
16
-5
-24% -$4.85K 0.01% 503
2024
Q1 		$20.2K Sell
21
-17
-45% -$16.2K 0.01% 459
2023
Q4 		$33.4K Hold
38
– – 0.01% 399
2023
Q3 		$31.3K Sell
38
-8
-17% -$6.29K 0.01% 374
2023
Q2 		$33.1K Hold
46
– – 0.02% 365
2023
Q1 		$37.8K Sell
46
-2
-4% -$1.51K 0.02% 330
2022
Q4 		$34.6K Hold
48
– – 0.02% 320
2022
Q3 		$33K Hold
48
– – 0.02% 301
2022
Q2 		$28K Hold
48
– – 0.02% 328
2022
Q1 		$34K Buy
48
+33
+220% +$20.9K 0.02% 337
2021
Q4 		$9K Buy
15
+13
+650% +$7.99K 0.01% 418
2021
Q3 		$1K Hold
2
– – ﹤0.01% 425
2021
Q2 		$1K Buy
+2
New +$1.01K ﹤0.01% 391

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Addison Advisors's REGN Position: Q1 2026 in Review

Addison Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 7.7% in Q1 2026, selling an estimated $766 and leaving 12 shares worth $9.27K. The position accounts for ﹤0.01% of the portfolio, ranked #665.

Addison Advisors first reported a position in REGN in Q2 2021 and has held it in 20 quarters since. The position peaked at $37.8K in Q1 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Addison Advisors held 12 shares of Regeneron Pharmaceuticals worth $9.27K as of Q1 2026.
  • Addison Advisors sold 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $766.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Addison Advisors's portfolio in Q1 2026, its #665 holding.
  • Addison Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Addison Advisors's Regeneron Pharmaceuticals position peaked at $37.8K in Q1 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Addison Advisors's 13F filing for Q1 2026, filed 8 May 2026.